Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors

Author： Gelfand Eli V Cannon Christopher P

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.15, Iss.3, 2006-03, pp. : 307-315

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 12, 2005-10 ,pp. : 2141-2144

Informa Healthcare

Access to resources Recommend Favorite

Discriminative stimulus effects of the cannabinoid CB₁ receptor antagonist rimonabant in rats

By Järbe Torbjörn Li Chen Vadivel Subramanian Makriyannis Alexandros

Psychopharmacology, Vol. 198, Iss. 4, 2008-07 ,pp. : 467-478

Springer Publishing Company

Access to resources Recommend Favorite

Cardiometabolic risk factors in T2DM improved by rimonabant

Inpharma, Vol. 1, Iss. 1655, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

CB1 Cannabinoid Receptors and their Associated Proteins

Current Medicinal Chemistry, Vol. 17, Iss. 14, 2010-05 ,pp. : 1382-1393

Bentham Science Publishers

Access to resources Recommend Favorite

Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB₁ receptor antagonist

By Järbe Torbjörn Harris Michele Li Chen Liu Qian Makriyannis Alexandros

Psychopharmacology, Vol. 177, Iss. 1-2, 2004-12 ,pp. : 35-45

Springer Publishing Company

Access to resources Recommend Favorite